Peter Willinger, an executive with more than a decade of financial management experience, has been appointed chief financial officer of Apogenix GmbH, a German developer of protein therapies for cancer. Mr Willinger was previously CFO of Sygnis Pharma AG (formerly LION bioscience AG) where he oversaw the company’s initial public offering of shares and subsequent capital increases.
Apogenix announced the appointment on 3 June 2015.
Copyright 2015 Evernow Publishing Ltd